JP2016525129A - 薬用水溶性抗真菌高分子化合物 - Google Patents

薬用水溶性抗真菌高分子化合物 Download PDF

Info

Publication number
JP2016525129A
JP2016525129A JP2016528298A JP2016528298A JP2016525129A JP 2016525129 A JP2016525129 A JP 2016525129A JP 2016528298 A JP2016528298 A JP 2016528298A JP 2016528298 A JP2016528298 A JP 2016528298A JP 2016525129 A JP2016525129 A JP 2016525129A
Authority
JP
Japan
Prior art keywords
polyconjugate
amphotericin
polymer
active drug
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016528298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525129A5 (enExample
Inventor
ウェン、グァンホイ
ワン、リューイー
ユウ、ドンファン
ヤン、ジンウェン
ワン、ハオジュン
Original Assignee
ベイジン ラブワールド バイオ−メディスン テクノロジー コーポレーション リミテッド
ベイジン ラブワールド バイオ−メディスン テクノロジー コーポレーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジン ラブワールド バイオ−メディスン テクノロジー コーポレーション リミテッド, ベイジン ラブワールド バイオ−メディスン テクノロジー コーポレーション リミテッド filed Critical ベイジン ラブワールド バイオ−メディスン テクノロジー コーポレーション リミテッド
Publication of JP2016525129A publication Critical patent/JP2016525129A/ja
Publication of JP2016525129A5 publication Critical patent/JP2016525129A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016528298A 2013-07-25 2014-02-08 薬用水溶性抗真菌高分子化合物 Pending JP2016525129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310315504 2013-07-25
CN201310315504.8 2013-07-25
PCT/CN2014/000146 WO2015010439A1 (zh) 2013-07-25 2014-02-08 药用水溶性抗真菌大分子化合物

Publications (2)

Publication Number Publication Date
JP2016525129A true JP2016525129A (ja) 2016-08-22
JP2016525129A5 JP2016525129A5 (enExample) 2016-09-29

Family

ID=51543906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528298A Pending JP2016525129A (ja) 2013-07-25 2014-02-08 薬用水溶性抗真菌高分子化合物

Country Status (10)

Country Link
US (1) US20160158376A1 (enExample)
EP (1) EP3025733A4 (enExample)
JP (1) JP2016525129A (enExample)
KR (1) KR101749004B1 (enExample)
CN (1) CN104055787B (enExample)
AU (1) AU2014295747B2 (enExample)
CA (1) CA2919145A1 (enExample)
HK (1) HK1220629A1 (enExample)
RU (1) RU2016103088A (enExample)
WO (1) WO2015010439A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669087B (zh) * 2018-07-02 2023-03-31 上海医药工业研究院 两性霉素b肽衍生物及其制备方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用
CN110577921B (zh) * 2019-05-28 2021-04-02 浙江工业大学 产两性霉素b的重组结节链霉菌及其应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508938A (ja) * 2005-09-22 2009-03-05 ハダシット メディカル リサーチ サーヴィスィズ アンド ディベロップメント リミテッド 治療上活性な化合物の結合体
JP2010516783A (ja) * 2007-01-29 2010-05-20 日東電工株式会社 多機能性薬物担体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1359473A (en) 1970-11-03 1974-07-10 Prodotti Antibiotici Spa Polyenic antibiotic
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
US5610264A (en) 1995-11-16 1997-03-11 Calwood Chemical Industries, Inc. Continuous process for polyaspartic acid synthesis
DE10129369C1 (de) * 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
DE10155098A1 (de) * 2001-11-09 2003-05-22 Supramol Parenteral Colloids Mittel zur Prävention von mykotischen Kontaminationen bei der Zell- und Gewebekultur bakteriellen, pflanzlichen, animalischen und humanen Ursprungs, bestehend aus Polyen-Makrolid-Konjugaten mit Polysacchariden
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101333044A (zh) * 2008-05-20 2008-12-31 北京能拓高科技有限公司 箱式组合式污水处理系统
EP2277547A1 (de) * 2009-07-20 2011-01-26 Merck Patent GmbH Epsilon-Polylysin-Konjugate und deren Verwendung
CN101935336B (zh) * 2010-09-01 2014-04-09 北京大学 一类水溶性紫杉烷类药物的制备方法和应用
CA2809934C (en) * 2010-09-02 2018-09-04 Nippon Kayaku Kabushiki Kaisha Process for producing drug-block copolymer composite and pharmaceutical preparation containing same
US8785569B2 (en) * 2011-11-22 2014-07-22 Original Biomedicals Co., Ltd. Drug carrier with chelating complex micelles and the application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508938A (ja) * 2005-09-22 2009-03-05 ハダシット メディカル リサーチ サーヴィスィズ アンド ディベロップメント リミテッド 治療上活性な化合物の結合体
JP2010516783A (ja) * 2007-01-29 2010-05-20 日東電工株式会社 多機能性薬物担体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, JPN6017000265, 2007, pages 2554 - 2557, ISSN: 0003477052 *

Also Published As

Publication number Publication date
KR101749004B1 (ko) 2017-06-19
CN104055787A (zh) 2014-09-24
CN104055787B (zh) 2017-04-26
RU2016103088A (ru) 2017-08-30
CA2919145A1 (en) 2015-01-29
US20160158376A1 (en) 2016-06-09
EP3025733A4 (en) 2017-09-20
EP3025733A1 (en) 2016-06-01
AU2014295747A1 (en) 2016-02-11
HK1220629A1 (en) 2017-05-12
AU2014295747B2 (en) 2016-08-25
WO2015010439A1 (zh) 2015-01-29
KR20160022915A (ko) 2016-03-02

Similar Documents

Publication Publication Date Title
US7538092B2 (en) Pharmaceutically active oligosaccharide conjugates
Volmer et al. Synthesis and biological evaluation of amphotericin B derivatives
CN103319479B (zh) 大黄酸小檗碱离子对化合物、制备方法及应用
US5606038A (en) Amphiphilic polyene macrolide antibiotic compounds
JP4228052B2 (ja) 水溶性ポリエン複合体
US10967065B2 (en) Compounds for treating biofilm infection
US9925275B2 (en) Amphotericin B derivatives
JP2000506899A (ja) ドキソルビシン耐性腫瘍に対する高活性を有するビス―アントラサイクリン
KR20070056113A (ko) 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제
JP2016525129A (ja) 薬用水溶性抗真菌高分子化合物
US20090186838A1 (en) Amphotericin Derivatives
CN118027128B (zh) 一种用于炎症协同治疗的地塞米松-亚麻酸前药自组装纳米粒及其应用
CN102604083B (zh) 聚合物修饰的脂质材料及其用途
CN107619428B (zh) 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用
CN115212221A (zh) 恩格列净和/或甜菊糖苷在制备治疗和/或预防炎症和/或其并发症的药物中的用途
ES2523507T3 (es) Conjugados terapéuticos de un polímero de dextrina y colistina
CN119431249B (zh) 菲并[9,10−d]咪唑季铵盐类衍生物及其制备方法和抗菌应用
US20240398843A1 (en) Glycyrrhizin-branched polyethylene glycol conjugate for treating cancer
JP4246358B2 (ja) ポリエンマクロライド系抗生物質の多量体
CN107573404B (zh) 鸟氨酸与门冬氨酸的二肽化合物的活性盐及其应用
CN105885027A (zh) Peg修饰的多粘菌素及其制备方法和应用
CN102988279B (zh) 松属素环糊精超分子包合物及其制备方法
CN119529003A (zh) 白蛋白结合型阿霉素前药及其自组装纳米粒和应用
CN1687051A (zh) 水溶性葛根素盐化合物及其制备方法
WO1998002168A1 (en) Complexes of n'-dimethylaminoacetylpartricin a dimethylaminoethylamide, or the salts thereof, and cholesterol 3-sulphate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170822